1.97

1.01% -0.02

Pre-market: 1.95 -0.02 -1.02%

Inmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

Inmune Bio Inc stock is traded at $1.97, with a volume of 434.03K. It is down -1.01% in the last 24 hours and up +35.86% over the past month. INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Previous Close:

$1.99

Open:

24h Volume:

434.03K

Relative Volume:

0.60

Market Cap:

$52.37M

Revenue:

$50,000

Net Income/Loss:

$-41.60M

P/E Ratio:

-1.1625

EPS:

-1.6946

Net Cash Flow:

$-20.20M

1W Performance:

-2.48%

1M Performance:

+35.86%

6M Performance:

+20.12%

1Y Performance:

-17.23%

1-Day Range:

$1.905

$2.04

1-Week Range:

$1.85

$2.165

52-Week Range:

$1.09

$3.244

Inmune Bio Inc Stock (INMB) Company Profile

Name

Inmune Bio Inc

Sector

Healthcare (1080)

Industry

Biotechnology (603)

Phone

(858) 964-3720

Address

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2026-08-06

Latest SEC Filings

INMB's Discussions on Twitter

Compare INMB vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INMB Inmune Bio Inc	1.97	52.90M	50,000	-41.60M	-20.20M	-1.6946
VRTX Vertex Pharmaceuticals Inc	482.00	121.95B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	675.19	70.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	874.74	52.94B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	183.29	38.35B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.37	36.40B	4.29B	577.22M	641.34M	4.2086

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Oct-21-24	Initiated	Alliance Global Partners	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Scotiabank	Sector Outperform
Jun-01-23	Initiated	Robert W. Baird	Outperform
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

Inmune Bio Inc Stock (INMB) Latest News

Jul 21, 2026

INMB Achieves Breakthrough in Umbilical Cord Tissue Processing - GuruFocus

Jul 21, 2026

Jul 20, 2026

INmune Bio And 2 Other Promising Penny Stocks To Consider - webull.com

Jul 20, 2026

INmune Bio Achieves Commercial-Ready Manufacturing Milestone for CORDStrom Platform Ahead of Planned Phase 3 Trial - Quiver Quantitative

Jul 20, 2026

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform - The Manila Times

Jul 20, 2026

INmune Bio's Cord-Tissue Process Supports Planned Phase 3 Trial - Stock Titan

Jul 20, 2026

Jul 17, 2026